Floatz logo

IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER

Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC

Seoul National University Hospitalmonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC cohort.

Asset / SponsorPhaseRating
Durvalumab
Seoul National University Hospital
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Carboplatin
Sichuan Cancer Hospital and Research Institute
Phase 2CCC
VOLITINIB
Hutchison Medipharma Limited
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Ivocizumab
Fudan University
Phase 2CCC
Toripalimab
Sichuan Cancer Hospital and Research Institute
Phase 2CCC
Pegargiminase
Polaris Group
Phase 1CC

Same molecule, other indications

IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER is also rated in:

malignant pancreatic neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
Borderline Resectable Pancreatic Ductal AdenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →